All In Biotech

Drug Trial Radar · NCT04641247

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib

Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

37

Planned (sponsor's estimate)

Start

Apr 16, 2021

Primary completion

Dec 28, 2026

Study completion Dec 28, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.

Conditions

  • Ovarian Neoplasms
  • Breast Neoplasms

Interventions

  • NiraparibDrug

    Niraparib tablets or capsules will be given once a day via the oral route.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI)Time frame: Up to 5 years
  2. Number of participants with clinically significant changes in Eastern Co-operative Oncology Group (ECOG) performance statusTime frame: Up to 5 years
  3. Number of participants with clinically significant changes in hematology and clinical chemistry parametersTime frame: Up to 5 years
  4. Number of participants with clinically significant changes in vital signsTime frame: Up to 5 years
  5. Number of participants with clinically significant changes in physical examinationTime frame: Up to 5 years
  6. Number of participants with use of concomitant medicationsTime frame: Up to 5 years

Locations

25 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tucson, Arizona · Completed

  • GSK Investigational Site

    Encinitas, California · Recruiting

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    Whittier, California · Completed

  • GSK Investigational Site

    Jacksonville, Florida · Completed

  • GSK Investigational Site

    Atlanta, Georgia · Recruiting

  • GSK Investigational Site

    Harvey, Illinois · Recruiting

  • GSK Investigational Site

    Boston, Massachusetts · Recruiting

  • GSK Investigational Site

    Grand Rapids, Michigan · Recruiting

  • GSK Investigational Site

    Morristown, New Jersey · Recruiting

  • GSK Investigational Site

    Lake Success, New York · Recruiting

  • GSK Investigational Site

    Charlotte, North Carolina · Recruiting

  • GSK Investigational Site

    Cleveland, Ohio · Completed

  • GSK Investigational Site

    Graz, Austria · Recruiting

  • GSK Investigational Site

    Vienna, Austria · Recruiting

  • GSK Investigational Site

    Kelowna, British Columbia, Canada · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Odense C, Denmark · Completed

  • GSK Investigational Site

    Nantes, France · Completed

  • GSK Investigational Site

    Nice, France · Completed

  • GSK Investigational Site

    Haifa, Israel · Recruiting

  • GSK Investigational Site

    Cremona, Italy · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.